Palatin Technologies Presents New Preclinical Data Highlighting Its Proprietary MC4R-Selective Peptide Agonist Programs At ObesityWeek 2026
Benzinga Newsdesk 3 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
- Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation
- Significant reductions in body weight and food intake demonstrated in preclinical models, with encouraging preliminary cardiovascular finding
- Proprietary lipidation technology supports once-weekly or potentially less frequent dosing; lead candidate PL2001 advancing toward first-in-human studies in the first half of 2027
PRINCETON, N.J., Nov. 16, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NASDAQ:PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists, today announced the presentation of new preclinical data highlighting the Company's proprietary MC4R-selective peptide agonist programs at ObesityWeek® 2026, being held November 14–17 in Washington, D.C.
